Staphylococcus Lugdunensis Prosthetic Joint Infection

Staphylococcus Lugdunensis Prosthetic Joint Infection: a Retrospective Cohort Study

Staphylococcus lugdunensis is a coagulase-negative staphylococcus belonging to the human commensal cutaneous flora, and has been little studied in the field of prosthetic joint infections. However, it shares many virulence traits with Staphylococcus aureus, including many adhesins and its ability to form biofilm, and the few series of cases reports a significant failure rate.

Study Overview

• Status: Completed
• Conditions: Staphylococcal Infections; Prosthetic Joint Infection
• Intervention / Treatment: Other: Prothestic joint infection due to Staphylococcus lugdunensis

• Study Type: Observational
• Enrollment (Actual): 84

Contacts and Locations

Study Locations

• France
  • Lyon, France, 69004
    • Hospices Civils de Lyon

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

patients having had IPA due to Staphylococcus lugdunensis

Description

Inclusion Criteria:

• infection of joint prosthesis (whatever its type) with Staphylococcus lugdunensis defined by the positivity of at least 2 gold-standard samples (joint puncture, intraoperative samples) with S. lugdunensis; OR
• a single positive gold-standard sample or positive blood cultures AND formal clinical, radiological, biological and / or pathological arguments in favor of an infection of joint prosthesis AND absence of other pathogenic agent

Exclusion Criteria:

• none

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Prothestic joint infection due to Staphylococcus lugdunensis; Patients having had a prosthetic joint infection with Staphylococcus lugdunensis	Other: Prothestic joint infection due to Staphylococcus lugdunensis; description of prosthetic joint infection with Staphylococcus lugdunensis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of PJI infection with Staphylococcus lugdunensis	proportion of patients having PJI infection with Staphylococcus lugdunensis, alone or with other bacteria	between 2010 and 2020
Description of PJI infection with Staphylococcus lugdunensis : type	type of PJI : knee or hip prosthesis	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of PJI infection with Staphylococcus lugdunensis : evolution	evolution of PJI :evolution between prosthesis placement and the onset of symptoms, gateway to infection	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of patients with PJI infection due to Staphylococcus lugdunensis	type of patients: age, CMI	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of patients with PJI infection due to Staphylococcus lugdunensis : follow up	duration of the follow up of patients	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of patients with PJI infection due to Staphylococcus lugdunensis : medical treatment	description and duration of antibiotics	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of patients with PJI infection due to Staphylococcus lugdunensis : surgical treatment	description of surgery performed : DAIR, one-step exchange, two-step exchange	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
rate of treatment failure	Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2021
• Primary Completion (Actual): April 1, 2021
• Study Completion (Actual): April 1, 2021

Study Registration Dates

• First Submitted: May 27, 2020
• First Submitted That Met QC Criteria: May 27, 2020
• First Posted (Actual): June 1, 2020

Study Record Updates

• Last Update Posted (Actual): June 16, 2021
• Last Update Submitted That Met QC Criteria: June 15, 2021
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Keywords: biofilm; Prosthetic Joint Infection; Staphylococcus lugdunensis
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Joint Diseases; Musculoskeletal Diseases; Arthritis; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Infections; Communicable Diseases; Arthritis, Infectious; Staphylococcal Infections
• Other Study ID Numbers: 20-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No